[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=278e58e05bd1dacae433acef53cda2d5fc03ec157c52dab126e1d34b78209e46",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735835700,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 132322280,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=278e58e05bd1dacae433acef53cda2d5fc03ec157c52dab126e1d34b78209e46"
    }
  },
  {
    "ts": null,
    "headline": "UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal",
    "summary": "Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH). Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration. Also Read: Big Biopharma Trails Behind The Market",
    "url": "https://finnhub.io/api/news?id=c9fd19c00f2abd4984846c94fefe4eb0bc7dba761e870b13fdab997c73100f7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735834532,
      "headline": "UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal",
      "id": 132240936,
      "image": "https://media.zenfs.com/en/Benzinga/7562d5f2a5e72709e5dac16d75204de8",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH). Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration. Also Read: Big Biopharma Trails Behind The Market",
      "url": "https://finnhub.io/api/news?id=c9fd19c00f2abd4984846c94fefe4eb0bc7dba761e870b13fdab997c73100f7f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=7282fab7bc21adcb63a847008f18b0d9f5ac894d0fe6bb268f7323db18c919ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735826421,
      "headline": "Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 132240937,
      "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=7282fab7bc21adcb63a847008f18b0d9f5ac894d0fe6bb268f7323db18c919ee"
    }
  },
  {
    "ts": null,
    "headline": "January Dow Dogs: 1 'Safer' Buy, And 5 With Promise",
    "summary": "Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.",
    "url": "https://finnhub.io/api/news?id=a2bfec130e38310a0339d2950fb14a024997156e837c950640f2806e609acfa0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735820503,
      "headline": "January Dow Dogs: 1 'Safer' Buy, And 5 With Promise",
      "id": 132240262,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/478792228/image_478792228.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.",
      "url": "https://finnhub.io/api/news?id=a2bfec130e38310a0339d2950fb14a024997156e837c950640f2806e609acfa0"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Alibaba Sells Sun Art At $2B Loss",
    "summary": "Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing",
    "url": "https://finnhub.io/api/news?id=f35c1b87852ed7e534e8002a37c9e81c5cc950bde06adc09208fdc6893149987",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735800792,
      "headline": "Wall Street Breakfast Podcast: Alibaba Sells Sun Art At $2B Loss",
      "id": 132237925,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368767105/image_1368767105.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Alibaba to sell stake in China's hypermarket chain Sun Art. Brand prescription drugs to rise an average 4.5% in 2025. Cybertruck blast driver identified; link to New Orleans attacker growing",
      "url": "https://finnhub.io/api/news?id=f35c1b87852ed7e534e8002a37c9e81c5cc950bde06adc09208fdc6893149987"
    }
  },
  {
    "ts": null,
    "headline": "Not A Year For The 2024 Dogs Of The Dow",
    "summary": "With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.",
    "url": "https://finnhub.io/api/news?id=28c6a445e8e9a1d5a082ef979aa21a6b9db0edad6601803c67794cbbb92d3e75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735795200,
      "headline": "Not A Year For The 2024 Dogs Of The Dow",
      "id": 132237169,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1854380206/image_1854380206.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.",
      "url": "https://finnhub.io/api/news?id=28c6a445e8e9a1d5a082ef979aa21a6b9db0edad6601803c67794cbbb92d3e75"
    }
  }
]